⏳ U.S. Approves First-Ever Human Trials for Cellular Rejuvenation

The startup Life Biosciences has received approval to launch clinical trials of its drug ER-100. This is the first therapy based on epigenetic reprogramming—a technique widely considered one of the most promising paths toward a potential "longevity pill."

The drug will be tested on patients with "eye stroke" (NAION) and glaucoma, which remains one of the leading causes of irreversible blindness worldwide. Around 60–80 million people live with glaucoma, and this number continues to grow as the global population ages.

Context. In 2006, Professor Shinya Yamanaka discovered a revolutionary method for reversing the biological age of cells, earning him the Nobel Prize in 2012. His work showed that mature cells can be converted into stem cells. For the next 20 years, the central challenge for scientists was to find a way to achieve "partial rejuvenation"—allowing cells to become younger without losing their specialization or turning into tumors. The ER-100 trial is the first real clinical answer to that challenge.

⚙️ How it is supposed to work?

Patients will receive microinjections of ER-100 directly into the eye. A disabled virus delivers genetic instructions into the cells, prompting the production of three Yamanaka factors. These proteins do not rewrite DNA; instead, they act on the epigenome—the system of chemical markers that controls how genes are switched on and off.

Inside the cell, they perform a kind of "deep clean," removing age-related epigenetic damage. As a result, an old cell begins to function as efficiently as a young one.

The process is activated by taking ordinary doxycycline tablets. The therapy can be stopped at any time simply by discontinuing the medication.

💡 If successful, the technology could be adapted to treat dementia, cardiovascular disease, muscle degeneration, and other "side effects of aging."

Do you think science can defeat aging?

❤️ — yes, it's just a disease
⚡️ — no, it's against nature

@hiaimediaen